Anthropic’s IPO order book closes today, Tuesday, November 17, 2026, with demand reported at close to seven times the shares on offer. That’s the headline number from Bloomberg, citing people familiar with the matter: investors have asked for seven times the 825 million Class A shares Anthropic is selling at $70 to $78 apiece. Lead banks Goldman Sachs and Morgan Stanley are expected to shut the book today, the final price is expected Wednesday evening, November 18, and shares are expected to start trading on Nasdaq as ANT on Thursday, November 19.
Before you get swept up in the excitement, keep two things straight. First, Anthropic itself has not confirmed the 7x figure — it comes from Bloomberg’s reporting, and the company has declined to comment on demand. Second, no final IPO price has been set. Some headlines over the past 48 hours have wrongly said the deal “priced at $78.” It hasn’t. The range is still $70 to $78, and the only thing that changes today is that the window for putting in an order closes.
What “7x oversubscribed” actually means
An oversubscribed order book sounds impressive, and it is — but the phrase gets misunderstood a lot, so let’s pin it down.
When a company goes public, its banks collect “indications of interest” — orders from big funds and, in this case, retail investors too — for the shares on offer. If investors ask for seven times more shares than exist, the book is 7x oversubscribed. For Anthropic, that math looks like this: 825 million shares on offer, multiplied by roughly seven, equals somewhere around 5.8 billion shares requested. At the top of the range, $78 a share, that’s roughly $450 billion of indicated demand chasing about $64.35 billion of stock. One independent tracker of the deal puts the same picture together: demand near 7x, the book closing Tuesday, and bankers weighing a price above the range.
That is a real signal of appetite. It is not a sale. IPO orders are not binding commitments. Large funds routinely ask for far more shares than they actually want, because they know the banks will cut them back. If a fund wants $500 million worth of shares and expects to receive only a fifth of what it asks for, it puts in a $2.5 billion order. The book looks enormous, but the money that actually changes hands is a fraction of it. Bloomberg’s reporting is a snapshot of indications, not a count of completed purchases. So read 7x as “a lot of people want in,” not as “$450 billion is about to flow into Anthropic.” The distinction is the difference between a strong debut and a fantasy.
The demand climb: from 2x to 7x in one week
The most telling part of this story isn’t the final number. It’s how fast the number moved. The roadshow only began on Monday, November 10, when Anthropic filed its amended prospectus and set the $70 to $78 range. In roughly a week, demand went from healthy to historic:
| When | Reported demand | Source |
|---|---|---|
| After day one of the roadshow (Nov 10) | About 2x the shares on offer | Reuters |
| Close of the third roadshow day (Nov 12) | About 6x the shares on offer | Reuters |
| Sunday, Nov 15 | Close to 7x the shares on offer | Bloomberg |
That last jump — from 6x to 7x over a weekend — is what turned this from a big IPO into the story of the week, and why bankers are now openly weighing a price above the range.
A quick note on what’s confirmed and what’s reported, because the two get blurred in fast-moving coverage. If a claim isn’t in a filing, treat it as reporting, not fact. That discipline is the only way to follow a deal moving this fast without getting burned by a headline.
| Claim | Status |
|---|---|
| Price range $70–$78, 825M shares | Confirmed — Anthropic’s S-1/A filing, Nov 10 |
| Amendment No. 3 filed Nov 17, terms unchanged, Nasdaq listing approved | Confirmed — SEC filing, Nov 17 |
| Orders near 7x the shares on offer | Reported — Bloomberg, citing people familiar, Nov 15 |
| Order book closes Tuesday, Nov 17 | Reported — Bloomberg, lead banks Goldman Sachs and Morgan Stanley |
| Final pricing Wednesday evening, Nov 18 | Expected — press reports and Anthropic’s IPO materials filed with the SEC; subject to regulatory clearance |
| Trading begins Thursday, Nov 19, as ANT | Expected — Nasdaq listing approved; subject to clearance |
| Bankers weighing a price above $78 | Reported — Bloomberg and Financial Times; no revised range filed |
If a claim isn’t in a filing, treat it as reporting, not fact. That discipline is the only way to follow a deal moving this fast without getting burned by a headline.
The $5 billion order that turned heads
The single biggest splash in the book came on Monday, November 16, when Altimeter Capital founder Brad Gerstner went on CNBC’s Halftime Report and said his firm is putting in a $5 billion order for Anthropic shares — five times his largest IPO bet ever, and roughly 8.2% of the entire offering at the $74 midpoint. One fund, one order, nearly a tenth of the deal.
Gerstner called Anthropic a cornerstone compounder for a long time — the kind of company you buy and hold for years, not flip on day one. That’s the language of a true believer, and it landed exactly as intended: by Monday afternoon, the $5 billion order was the second-biggest story in the deal after the 7x figure itself.
But the same caveat applies here, and it’s worth saying plainly. Gerstner’s $5 billion is an intended order, not a confirmed allocation. Altimeter will not receive $5 billion of shares. It will receive whatever the banks decide to give it after the book closes and the deal is priced — and with the book at 7x, that will be a fraction of what was asked. The order is a statement of intent and a signal to the market. It is not a purchase receipt.
The deal itself: what Anthropic is actually selling
Anthropic is offering 825 million Class A shares at $70 to $78 each — 801.35 million new shares from the company, plus 23.65 million from the seven co-founders. At $70, the offering raises about $57.75 billion; at $78, about $64.35 billion, making it the largest IPO on record by gross proceeds. The Big Ant’s daily rollup confirms the same filed picture: Amendment No. 3 this morning left the terms unchanged, the Nasdaq listing is approved, and the range is still $70–$78.
At the top of the range, the deal implies a fully diluted valuation of roughly $1.4 trillion. That’s the number that has drawn the most disbelief — and the most skepticism, which we’ll come to. For context, it would put a company founded in 2021, which only filed its first public S-1 on October 26, among the most valuable companies on earth on its first day of trading.
There’s also a second, quieter deal running alongside the public offering. Seven of the biggest names in tech — Google and NVIDIA at $10 billion each, plus AMD, Broadcom, Micron, Microsoft, and TSMC — have agreed to buy $26 billion of Anthropic stock in a concurrent private placement, at whatever the IPO price turns out to be. It’s a vote of confidence, but also a reminder of how intertwined this deal is with the AI supply chain: Anthropic’s biggest suppliers are also its biggest new shareholders.
For the full background — the filing, the roadshow, and the range — see our breakdown of the $70–$78 price range and the November 19 trading date and the roadshow and Q3 numbers from the November 10 filing. There’s also a wrinkle worth knowing: Chinese and Hong Kong investors are blocked from the offering under US export-control rules.
Retail investors: your deadline is 4 p.m. ET today
US retail orders close at 4:00 p.m. Eastern today, Tuesday, November 17. That’s the deadline at the participating brokers: Charles Schwab, Fidelity, Robinhood (including TradePMR), SoFi, and Morgan Stanley’s E-Trade. If you haven’t submitted an indication of interest by then, you’re out of the IPO allocation process. You can still buy ANT on the open market when trading starts Thursday — but you’ll be paying whatever the market price is that morning, not the IPO price.
A few honest points if you’re considering putting in an order before 4 p.m.:
- Up to 20% of the offering is reserved for retail investors. That’s up to 165 million shares, or about $12.9 billion at $78. Retail isn’t an afterthought in this deal, but it’s still the smaller slice.
- Asking doesn’t mean receiving. With the book at roughly 7x, retail orders will be scaled back just like institutional ones. If you ask for $5,000 worth, expect considerably less — and possibly nothing at all if demand at your broker is especially heavy. (I work through the math below.)
- You don’t pay until the price is set. An indication of interest isn’t a charge to your account. If the deal prices and you receive an allocation, that’s when the purchase happens.
- The IPO price and the first trading price are two different numbers. In hot IPOs, shares often open well above the IPO price on day one — which means anyone buying on Thursday morning is paying a premium to the IPO price, sometimes a large one.
None of this is financial advice. But if you were planning to participate, the decision point is today at 4 p.m., not Thursday.
Will it price above $78?
This is the question everyone in the market is asking this morning, and the honest answer is: probably, but nothing is filed yet.
Bloomberg and the Financial Times have both reported that the banks are weighing pricing the deal above the $78 top of the range. With the book at 7x, the logic is hard to argue with — when demand is seven times supply, the market is telling you the price is too low. Raising the price captures more money for the company and its selling stockholders, and it reduces the size of the first-day “pop” that hands a windfall to IPO buyers at the company’s expense.
Watch for it tomorrow. If the deal “priced above the range,” that’s the moment the 7x demand translated into a higher price. If it prices at $78, the banks chose to leave money on the table in exchange for a cleaner debut and a happy first-day pop.
The “$78” headlines are wrong — here’s the correction
No final price has been announced. The $78 figure is the top of the filed range — the maximum price in the $70 to $78 band set on November 10. A range is not a price. The final price gets set on Wednesday evening, November 18, when the banks close the book, tally the orders, and agree on a number with Anthropic. Until that announcement lands, anyone telling you the IPO “priced at $78” is confusing the ceiling with the outcome.
Why does this matter? Because real people make real decisions off these headlines. A retail investor who reads “priced at $78” might think the window has closed, or that $78 is the price they’ll pay, or that the deal is done. None of that is true yet. The book closes today. The price gets set tomorrow. Trading starts Thursday. That’s the sequence, and no headline can fast-forward it.
What 7x oversubscription means for your allocation
Let’s do the math honestly.
Say you’re a retail investor and you put in an order for $5,000 of Anthropic stock at the $74 midpoint. That would buy about 67 shares if you received your full order. But with the book at roughly 7x oversubscribed, a simple pro-rata cut would give you about one-seventh of what you asked for — roughly $714 worth, or about 9 or 10 shares.
That’s an illustration, not a promise. Real IPO allocations don’t work by clean division. The banks allocate by investor type, by broker, by order size, and by relationship. Retail allocations in hot deals are often much smaller than the headline multiple suggests, because institutions get priority and retail gets what’s left. Some brokers use lottery systems. Some fill small orders first. Some fill none at all below a threshold. The honest summary is this: if you asked for $5,000, expect a few hundred dollars’ worth, and don’t be surprised if it’s less — or zero.
The institutional side is the same story at a different scale. Altimeter’s $5 billion order, at a one-seventh pro-rata cut, would work out to roughly $714 million of shares — still an enormous allocation, but a long way from $5 billion. And in practice, a marquee name like Altimeter may get a better fill than the average, because banks reward the funds that anchor a book.
There’s a second-order effect worth understanding, too. Because everyone knows they’ll be cut back, everyone inflates their order. That inflation is part of why the book reads 7x in the first place. The true demand — what investors would actually buy if they received every share they asked for — is lower than 7x, and nobody outside the banks’ syndicate desks knows by how much. So when you see “7x oversubscribed,” think of it as an upper bound on enthusiasm, not a precise measurement of it.
The skeptic’s case: dot-com echoes
Not everyone is cheering. The most prominent skeptic so far is AustralianSuper, Australia’s largest pension fund — and notably, a pre-IPO investor in Anthropic, not an outsider throwing stones. Its chief investment officer warned, via Bloomberg, that the roughly $1.4 trillion valuation reflects a level of exuberance that echoes the dot-com era.
That’s a heavy charge, and it’s worth taking seriously precisely because of who said it: AustralianSuper already owns a piece of Anthropic and benefits if the IPO prices high. Warning about exuberance anyway is the opposite of talking your own book.
The concern, in plain terms, is this: a $1.4 trillion valuation prices in years of flawless execution — revenue growth, margin expansion, and a durable lead in AI models — before any of it has fully happened. Anthropic is a real company with real revenue and a genuinely leading product in Claude. But the valuation assumes the future goes very right, for a very long time.
The betting markets, for what they’re worth, have started to lean the same way. Polymarket odds of Anthropic closing its debut at a $1.5 trillion valuation were 23% on November 17, down 14 points in 24 hours. That’s a betting market, not a forecast — but the direction is interesting: even as the order book swelled to 7x, the crowd betting on the most extreme debut outcome got less confident, not more.
None of this means the IPO will fail. A deal can be both wildly oversubscribed and richly valued at the same time — in fact, that’s usually how the biggest IPOs work. It does mean the margin for error after Thursday is thin. When a stock debuts at $1.4 trillion, there is no room for a disappointing quarter to be shrugged off.
What this means for Claude users: nothing yet
If you use Claude every day — for writing, coding, research, or just asking it questions — here’s the box that matters most to you: this IPO changes nothing about Claude today.
An IPO changes who owns a company, not what the company sells. Claude’s pricing, plans, features, and availability don’t change because Anthropic’s shares start trading on Nasdaq. The free tier doesn’t get worse on Thursday morning. Pro and Team subscribers don’t get a new bill. The model doesn’t get better or worse because a stock ticker exists.
What could change, over time, is the pressure. Public companies report earnings every quarter, and their share prices react to every number. Anthropic has spent its life as a private company that could invest for the long term without explaining itself to the market every 90 days. From Thursday onward, a $1.4 trillion valuation sets expectations that are very hard to meet quietly.
For now, though, the honest answer to “what does the IPO mean for me as a Claude user?” is: nothing yet. Keep using the product. Watch what the company does with the roughly $60 billion it’s about to raise. The interesting questions — what gets built, what gets priced, what gets prioritized — come later.
What happens next
Here’s the sequence from here, as reported and as filed:
- Today, Tuesday, November 17: The order book closes. US retail orders are due by 4:00 p.m. ET. Goldman Sachs and Morgan Stanley finalize the tally.
- Wednesday, November 18: The final IPO price is expected to be set in the evening. European retail orders close at 4 p.m. CET. This is when we learn whether the deal priced at $78, inside the range, or above it.
- Thursday, November 19: Shares are expected to begin trading on Nasdaq under the ticker ANT. Anyone with a brokerage account that offers US stocks can buy ANT at the market price — which may sit well above the IPO price.
One more date to keep in mind, from the filing itself: the lock-up terms free up to 1.6 billion additional shares — nearly twice the offering — for sale by early February, on a staggered schedule starting on the first trading day. The filing doesn’t say how many holders plan to sell, but it’s the next supply event after the debut, and it will test whether the 7x demand was durable or just debut-week excitement.
The story of this IPO will be written in stages: the book today, the price tomorrow, the first trade Thursday, then the slow grind of public-company life. Today’s number — 7x — is the loudest of them. Remember what it is: a reported snapshot of demand, not a promise of what happens next.
This article is for information only, not financial advice. IPO investing carries risk, including the risk of losing money.
Frequently Asked Questions
Is Anthropic’s IPO really 7x oversubscribed?
Close to it, according to Bloomberg, which reported on Sunday, November 15 that orders had reached close to seven times the 825 million shares on offer, citing people familiar with the matter. That’s up from about 6x reported on November 12–13. Anthropic has not confirmed the figure, and IPO orders are not binding — funds routinely ask for more shares than they want because they expect to be cut back — so 7x measures indicated appetite, not completed purchases.
When does Anthropic’s IPO order book close?
The order book is expected to close today, Tuesday, November 17, 2026, according to Bloomberg’s reporting on the plans of lead banks Goldman Sachs and Morgan Stanley. US retail investors must submit orders by 4:00 p.m. ET today through participating brokers — Charles Schwab, Fidelity, Robinhood (including TradePMR), SoFi, and Morgan Stanley E-Trade. European retail investors have until 4 p.m. CET on Wednesday, November 18.
Has Anthropic’s IPO priced at $78?
No. Some headlines have wrongly stated that the deal “priced at $78.” The $78 figure is the top of the filed $70–$78 range set on November 10. No final price has been announced; it is expected to be set on Wednesday evening, November 18. Bankers are reportedly weighing a price above the $78 top, but no revised range has been filed as of Tuesday morning.
When will Anthropic stock start trading, and what is the ticker?
Shares are expected to begin trading on Thursday, November 19, 2026, on Nasdaq under the ticker symbol ANT. The Nasdaq listing has been approved, and Amendment No. 3 to Anthropic’s S-1, filed November 17, left the terms unchanged. Trading is subject to regulatory clearance, and the market price on day one may differ significantly from the IPO price.
How much is Anthropic raising, and what is the valuation?
At the filed $70–$78 range, the 825 million-share offering raises about $57.75 billion at the bottom and about $64.35 billion at the top. At $78, the deal implies a fully diluted valuation of roughly $1.4 trillion. Seven tech companies are also buying $26 billion of stock in a concurrent private placement at the IPO price.
What does the Anthropic IPO mean for Claude users?
Nothing yet. An IPO changes who owns the company, not what it sells. Claude’s pricing, plans, features, and availability don’t change when trading begins. Over time, being a public company brings quarterly earnings pressure and shareholder scrutiny, which could shape Anthropic’s priorities — but there is no change to the product on day one.
